Skip to content
Dr. Gaurang Ramesh

Home Articles

Microbiome learning path · Chapter 11

Faecal transplant, phages and what is coming

One microbiome treatment is established: a transplant of donor stool for a bowel infection that keeps returning. Everything else in this chapter is on the way, not here. Researchers are moving from whole stool towards purified spores, mixtures of a few named strains, single engineered bacteria and viruses that remove one bacterium at a time. This chapter explains what each is, what trials have shown so far, where they have failed, and the limit that still holds: nobody can yet steer a person’s microbiome to order.

On this page In short Where it is heading Faecal transplant Other conditions Safety Without the stool Phages Fungi and Candida Engineered bacteria Personal diets The limit When to see a doctor Questions

In short

Where is microbiome treatment heading?

From the crude towards the precise.

From crude to precise1Whole donor stooleverything, known and unknownin use2Purified sporesdonor stool, cleaned and narrowedapproved abroad3A defined mixturea few named strains, grown in a labin trials4One engineered bacteriumbuilt to do a single jobearly trials5Phagesviruses that remove one bacteriumearly trials

Five rungs. Each step down the list is narrower, better defined and further from routine use.

Whole stool works, but nobody knows exactly what in it does the work. Each later step tries to keep the benefit and discard the unknowns.

What is a faecal transplant, and what does it treat?

Stool from a screened, healthy donor is processed and placed in a patient’s bowel, to restore a community of bacteria that antibiotics have destroyed.

The idea is old. A gastroenterology journal has described it as a 1,700-year-old practice, and surgeons reported using faecal enemas for a severe bowel infection in 1958.

Its modern proof came in 2013. In the first randomised trial in people whose C. difficile infection kept returning, 81% recovered after one infusion of donor stool, compared with 31% of those given an antibiotic alone. Guidelines now recommend it for that infection.

Faecal transplant is not performed at my centre at present. For how it is done, what to ask a hospital that offers it, and where regulation stands in India, see faecal transplant in India.

Does it work for anything else?

Not reliably yet.

Ulcerative colitis. In a trial of 73 adults with mild to moderate disease, 32% of those given donor stool were in remission at eight weeks, compared with 9% of those given their own stool back. Of the 12 who responded, 5 were still in remission a year later. The researchers called it a preliminary study.

Irritable bowel syndrome. Two randomised trials reached opposite conclusions.

Two trials in IBS, two answersTrial oneplacebotransplanta clear benefitTrial twoplacebotransplantno differenceBars for trial one show the share who responded.Bars for trial two show symptom scores, which were alike.This is why guidelines keep transplant for IBS inside trials.

Same treatment, opposite results. One trial used a carefully chosen donor. The other found no difference from placebo.

When good trials disagree this sharply, the honest position is that it is not known. American guidelines advise against faecal transplant for irritable bowel syndrome, ulcerative colitis and Crohn’s disease outside clinical trials.

How safe is it?

Safer than it sounds, and less safe than it should be.

Home methods with unscreened stool carry a real risk of serious infection and should never be attempted.

These risks are the reason for everything that follows in this chapter.

Can the useful part be given without the stool?

That is where the field is moving.

Purified spores

A capsule of bacterial spores purified from donor stool. In a trial, the infection returned in 12% of patients given the capsule, compared with 40% given a dummy capsule.

A defined mixture

Eight named strains of bacteria, grown in a laboratory, with no donor needed. In a trial, the infection returned within eight weeks in about 14% of those given the higher amount, compared with about 45% on placebo. The researchers asked for a larger trial to confirm it.

A filtrate with no living bacteria

In 5 patients, stool that had been filtered to remove all living bacteria still restored normal bowel habit. This suggests that part of the benefit comes from what bacteria leave behind, or from their viruses.

The last finding is small, and important. It means the active part of a transplant may not be the bacteria alone.

What are phages, and can they be used as treatment?

Phages are viruses that infect bacteria. They do not infect human cells. The gut holds vast numbers of them, and each kind attacks particular bacteria. See chapter 1.

A phage attacks one kind of bacteriumits targetdestroyeda neighbourleft aloneanotherleft aloneAn antibiotic removes many kinds at once. A phage isnarrow, which is its promise and its difficulty.

A narrow weapon. A phage removes one kind of bacterium and leaves its neighbours alone.

That narrowness is the attraction. An antibiotic removes many kinds of bacteria at once. A phage could, in principle, remove one harmful kind and nothing else.

So far the results in the gut are mixed.

Phage treatment for gut disease is at the stage of early trials. It is not available as routine care.

What about the fungi in the gut?

They are few, and they are less stable than the bacteria. In a survey of healthy adults in the Human Microbiome Project, gut fungi were low in variety and dominated by yeasts. A person’s fungi changed so much over time that one sample resembled the same person’s next sample no more than it resembled a stranger’s.

That instability is why a single stool report listing a yeast tells so little, and why there is no treatment aimed at “balancing” gut fungi.

Can bacteria be engineered to treat disease?

In principle, yes, and the first human studies have been done.

In one, a harmless gut bacterium was engineered to break down a substance that builds up in a rare inherited disorder. In healthy volunteers and patients it was safe, with mild gut side effects. Everyone cleared the bacterium within four days of the last dose, and blood and urine tests showed that it was doing its job while it was present.

It is a proof of mechanism in a small study, not a treatment. Note what it shares with every probiotic: the bacterium did not stay.

Will my diet one day be matched to my gut bacteria?

Possibly. The first pieces are in place.

The same meal, different responsesan identical mealrise in blood sugar after the mealIn a study of 1,002 adults, responses to identical mealsdiffered widely. The curves are an illustration.

One meal, many responses. People differ more than a single diet chart allows for.

In a study of 1,002 adults, blood sugar, blood fats and insulin after identical meals differed widely from person to person. A person’s gut bacteria explained more of the difference in blood fats than the composition of the meal did, though both shares were small. For blood sugar, the meal mattered more.

In an earlier study, a diet built on each person’s predicted blood sugar response lowered blood sugar after meals.

What is missing is proof that eating this way prevents disease, and a test that is accurate and practical enough to use in a clinic. Commercial tests that promise a diet from a stool sample are ahead of the evidence. See gut microbiome testing.

What is the honest limit?

Three things are true together.

The treatments in this chapter will matter for specific diseases. For everyone else, the plate remains the tool that works.

From my practice

Patients ask me about faecal transplant more often than its evidence justifies, usually for bloating, irritable bowel syndrome or weight. I do not perform it at present, and for those problems I would not advise it anywhere outside a trial. For C. difficile infection that keeps returning it is a recommended treatment, and I make sure those patients know it exists and what to ask.

I follow the newer work closely, because defined mixtures and phages may one day replace both stool and some antibiotics. Until a treatment has passed a proper trial, I do not offer it.

What this page saysHow it is known
Donor stool ended recurrent C. difficile infection in 81%, against 31%The first randomised trial
Donor stool brought remission in ulcerative colitis in 32%, against 9%A randomised trial in 73 adults
Transplant for IBS gave opposite resultsTwo randomised, placebo-controlled trials
A drug-resistant infection passed from a donor, with one deathA case report of two patients
A mixture of eight named strains reduced recurrenceA randomised phase 2 trial
Filtered stool with no living bacteria still helpedA study of 5 patients
Phages by mouth were safe but did not help childhood diarrhoeaA randomised trial in Bangladesh
A five-phage combination suppressed a harmful bacteriumMice; safety shown in healthy volunteers
An engineered bacterium worked while present and then clearedA first study in people
Responses to identical meals differ widelyA study of 1,002 adults

When should I see a doctor?

See a doctor for diarrhoea that begins during or after a course of antibiotics, especially with fever or blood, and for any bowel symptom that lasts more than three to four weeks. Do not seek a faecal transplant, a phage product or an imported microbiome medicine on your own.

Questions patients ask me

Can I have a faecal transplant for IBS or bloating?

Not as routine care. Two good trials disagreed, and guidelines advise it only within clinical trials.

Is a “poop pill” the same as a transplant?

Capsules can carry donor stool or purified spores from it. In trials they have worked for C. difficile infection that keeps returning. They are medicines, given after screening, not something to buy online.

Are phages safe?

In the studies so far, phages taken by mouth have been safe. Whether they help a gut disease has not been shown. Products sold as phages for gut health have not been through such trials.

Will a microbiome test tell me what to eat?

Not yet with confidence. Research shows people respond differently to the same meal, and that gut bacteria are part of the reason. The step from there to a reliable personal diet has not been proven.

When will these treatments reach India?

I cannot say. A review in 2025 found that India had no specific rules yet for faecal transplant. Newer treatments will need trials and approval before any hospital should offer them.

Sources

This page is written for patients and is based on the guidelines and studies below. It is for education and does not replace a consultation.

  1. Trial of donor faeces infusion for recurrent C. difficile infection. van Nood E et al. N Engl J Med. 2013. PubMed 23323867
  2. American Gastroenterological Association guideline on faecal microbiota-based therapies. Peery AF et al. Gastroenterology. 2024. PubMed 38395525
  3. Report of drug-resistant infection transmitted by faecal microbiota transplant. DeFilipp Z et al. N Engl J Med. 2019. PubMed 31665575
  4. Trial of an oral microbiome medicine for recurrent C. difficile infection. Feuerstadt P et al. N Engl J Med. 2022. PubMed 35045228
  5. Letter on the history of faecal microbiota transplantation (title only; no abstract on PubMed). Zhang F et al. Am J Gastroenterol. 2012. doi:10.1038/ajg.2012.251
  6. Surgical report of faecal enemas for pseudomembranous enterocolitis (title only; no abstract on PubMed). Eiseman B et al. Surgery. 1958. PubMed 13592638
  7. Randomised trial of a defined mixture of eight bacterial strains to prevent recurrent C. difficile infection. Louie T et al. JAMA. 2023. doi:10.1001/jama.2023.4314
  8. Study of sterile faecal filtrate in 5 patients with C. difficile infection. Ott SJ et al. Gastroenterology. 2017. doi:10.1053/j.gastro.2016.11.010
  9. Randomised trial of faecal microbiota transplantation in 73 adults with ulcerative colitis. Costello SP et al. JAMA. 2019. doi:10.1001/jama.2018.20046
  10. Randomised placebo-controlled trial of faecal microbiota transplantation in irritable bowel syndrome. El-Salhy M et al. Gut. 2020. doi:10.1136/gutjnl-2019-319630
  11. Randomised placebo-controlled trial of faecal transplant capsules in 48 people with diarrhoea-predominant irritable bowel syndrome. Aroniadis OC et al. Lancet Gastroenterol Hepatol. 2019. doi:10.1016/S2468-1253(19)30198-0
  12. Review of the bacteriophages of the human gut. Shkoporov AN, Hill C. Cell Host Microbe. 2019. doi:10.1016/j.chom.2019.01.017
  13. Randomised trial of oral phages in children with bacterial diarrhoea in Bangladesh. Sarker SA et al. EBioMedicine. 2016. doi:10.1016/j.ebiom.2015.12.023
  14. Study of a phage combination against a bacterium linked with inflammatory bowel disease. Federici S et al. Cell. 2022. doi:10.1016/j.cell.2022.07.003
  15. Study of gut fungi in healthy adults of the Human Microbiome Project. Nash AK et al. Microbiome. 2017. doi:10.1186/s40168-017-0373-4
  16. First study in people of an engineered gut bacterium for a rare inherited disorder. Puurunen MK et al. Nat Metab. 2021. doi:10.1038/s42255-021-00430-7
  17. Study of responses to identical meals in 1,002 adults. Berry SE et al. Nat Med. 2020. doi:10.1038/s41591-020-0934-0
  18. Study predicting each person’s blood sugar response to meals. Zeevi D et al. Cell. 2015. doi:10.1016/j.cell.2015.11.001
  19. Review of faecal microbiota transplantation and its regulation worldwide, including India. Indian J Med Res. 2025;161(2):113-119. PubMed 40257135

Have a question about your own symptoms?

An article can explain a condition. It cannot examine you. Bring your reports and your questions to a consultation at Arka Anugraha Hospital, JP Nagar, Bengaluru.

Book on WhatsApp+91 80737 37505